Exact Mass: 487.1105758

Exact Mass Matches: 487.1105758

Found 87 metabolites which its exact mass value is equals to given mass value 487.1105758, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Luciferyl sulfate

Renilla luciferyl sulfate

C26H21N3O5S (487.12018560000007)


   
   

Dasatinib

N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide

C22H26ClN7O2S (487.1557126000001)


Dasatinib is only found in individuals that have used or taken this drug. It is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR&beta. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Pyranocyanin B

7-(3,4-dihydroxyphenyl)-11-hydroxy-3-methyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2λ⁴,8-dioxatricyclo[7.3.1.0⁵,¹³]trideca-1,3,5(13),6,9,11-hexaen-2-ylium

C24H23O11 (487.1240308)


Pyranocyanin B is found in fruits. Pyranocyanin B is a constituent of the seeds of Ribes nigrum (blackcurrant) Constituent of the seeds of Ribes nigrum (blackcurrant). Pyranocyanin B is found in fruits.

   

2,2,2-Trifluoro-N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)-2-propanyl)acetamide

2,2,2-Trifluoro-N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)-2-propanyl)acetamide

C25H21F4N3O3 (487.15189640000006)


   

(2S)-3-[[2-[(5R)-3-(4-Carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]-2-[(3-methylphenyl)sulfonylamino]propanoic acid

(2S)-3-[[2-[(5R)-3-(4-Carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]-2-[(3-methylphenyl)sulphonylamino]propanoic acid

C22H25N5O6S (487.152547)


   

Malvidin 3-alpha-L-galactoside

2-(3-ethenyl-5-methoxy-4-methylphenyl)-5,7-dihydroxy-3-{[(2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1λ⁴-chromen-1-ylium

C25H27O10 (487.1604142)


Malvidin 3-alpha-l-galactoside is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Malvidin 3-alpha-l-galactoside can be found in highbush blueberry, which makes malvidin 3-alpha-l-galactoside a potential biomarker for the consumption of this food product.

   
   
   

11,11-dechloro-4-demethylrebeccamycin|12-[beta-D-glucopyranosyl]-6,7,12,13-tetrahydroindolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione

11,11-dechloro-4-demethylrebeccamycin|12-[beta-D-glucopyranosyl]-6,7,12,13-tetrahydroindolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione

C26H21N3O7 (487.1379436)


   
   
   

CAY10575

5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[4-(methylsulfonyl)phenyl]methoxy]-2-thiophenecarboxamide

C22H21N3O6S2 (487.08717260000003)


   
   

Cys Asp His Asn

(3S)-3-[(2R)-2-amino-3-sulfanylpropanamido]-3-{[(1S)-1-{[(1S)-2-carbamoyl-1-carboxyethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Cys Asp Asn His

(3S)-3-[(2R)-2-amino-3-sulfanylpropanamido]-3-{[(1S)-2-carbamoyl-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Cys His Asp Asn

(3S)-3-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-{[(1S)-2-carbamoyl-1-carboxyethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Cys His Asn Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]butanedioic acid

C17H25N7O8S (487.148525)


   

Cys Asn Asp His

(3S)-3-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Cys Asn His Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]butanedioic acid

C17H25N7O8S (487.148525)


   

Asp Cys His Asn

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-carboxypropanamido]-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanoic acid

C17H25N7O8S (487.148525)


   

Asp Cys Asn His

(3S)-3-amino-3-{[(1R)-1-{[(1S)-2-carbamoyl-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}ethyl]carbamoyl}-2-sulfanylethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Asp His Cys Asn

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]-3-carbamoylpropanoic acid

C17H25N7O8S (487.148525)


   

Asp His Asn Cys

(3S)-3-amino-3-{[(1S)-1-{[(1S)-2-carbamoyl-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}ethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Asp Asn Cys His

(3S)-3-amino-3-{[(1S)-2-carbamoyl-1-{[(1R)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-sulfanylethyl]carbamoyl}ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Asp Asn His Cys

(3S)-3-amino-3-{[(1S)-2-carbamoyl-1-{[(1S)-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

His Cys Asp Asn

(3S)-3-[(2R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]-3-{[(1S)-2-carbamoyl-1-carboxyethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

His Cys Asn Asp

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]-3-carbamoylpropanamido]butanedioic acid

C17H25N7O8S (487.148525)


   

His Asp Cys Asn

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carboxypropanamido]-3-sulfanylpropanamido]-3-carbamoylpropanoic acid

C17H25N7O8S (487.148525)


   

His Asp Asn Cys

(3S)-3-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-{[(1S)-2-carbamoyl-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

His Asn Cys Asp

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]-3-sulfanylpropanamido]butanedioic acid

C17H25N7O8S (487.148525)


   

His Asn Asp Cys

(3S)-3-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]-3-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Asn Cys Asp His

(3S)-3-[(2R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Asn Cys His Asp

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]butanedioic acid

C17H25N7O8S (487.148525)


   

Asn Asp Cys His

(3S)-3-[(2S)-2-amino-3-carbamoylpropanamido]-3-{[(1R)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-sulfanylethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Asn Asp His Cys

(3S)-3-[(2S)-2-amino-3-carbamoylpropanamido]-3-{[(1S)-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   

Asn His Cys Asp

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]butanedioic acid

C17H25N7O8S (487.148525)


   

Asn His Asp Cys

(3S)-3-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}propanoic acid

C17H25N7O8S (487.148525)


   
   

Dasatinib

Dasatinib

C22H26ClN7O2S (487.1557126000001)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Pyranocyanin B

3-(3,4-dihydroxyphenyl)-11-hydroxy-7-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2$l^{4},8-dioxatricyclo[7.3.1.0^{5,13}]trideca-1(12),2,4,6,9(13),10-hexaen-2-ylium

C24H23O11 (487.1240308)


   
   
   

2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl azide

2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl azide

C26H21N3O7 (487.1379436)


   

L-Histidine,N,1-bis(2,4-dinitrophenyl)-

L-Histidine,N,1-bis(2,4-dinitrophenyl)-

C18H13N7O10 (487.0723878)


   

(3R)-3-Amino-4-(2,5-difluorophenyl)-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-butanone phosphate (1:1)

(3R)-3-Amino-4-(2,5-difluorophenyl)-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-butanone phosphate (1:1)

C16H19F5N5O5P (487.10439140000005)


   

5,7-dichloro-2-trityl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid

5,7-dichloro-2-trityl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid

C29H23Cl2NO2 (487.1105758)


   

(8-(benzyloxy)-5-[(1R)-2-broMo-1-{[tert-butyl(diMethyl)silyl]oxy}ethyl]quinolin-2(1H)-one )

(8-(benzyloxy)-5-[(1R)-2-broMo-1-{[tert-butyl(diMethyl)silyl]oxy}ethyl]quinolin-2(1H)-one )

C24H30BrNO3Si (487.117821)


   

Zoliflodacin

Zoliflodacin

C22H22FN5O7 (487.1503194)


D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D023303 - Oxazolidinones C254 - Anti-Infective Agent > C258 - Antibiotic D004791 - Enzyme Inhibitors

   

2-(4-bromophenyl)-4,6-di(naphthalen-2-yl)-1,3,5-triazine

2-(4-bromophenyl)-4,6-di(naphthalen-2-yl)-1,3,5-triazine

C29H18BrN3 (487.0684008)


   

ethyl 5-(benzyloxy)-6-broMo-2-(3-ethoxy-3-oxopropyl)-1-Methyl-1H-indole-3-carboxylate

ethyl 5-(benzyloxy)-6-broMo-2-(3-ethoxy-3-oxopropyl)-1-Methyl-1H-indole-3-carboxylate

C24H26BrNO5 (487.0994246000001)


   

2-O-benzyl 1-O-tert-butyl (2S,4R)-4-[(4-bromophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxylate

2-O-benzyl 1-O-tert-butyl (2S,4R)-4-[(4-bromophenyl)methyl]-5-oxopyrrolidine-1,2-dicarboxylate

C24H26BrNO5 (487.0994246000001)


   

2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide

2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide

C25H21F4N3O3 (487.15189640000006)


   

Fulacimstat

Fulacimstat

C23H16F3N3O6 (487.0991152)


C78274 - Agent Affecting Cardiovascular System D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor

   

cytidine diphosphate choline

cytidine diphosphate choline

C14H25N4O11P2- (487.099502)


N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics D002491 - Central Nervous System Agents > D018697 - Nootropic Agents COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Fonazine mesylate

Fonazine mesylate

C20H29N3O5S3 (487.12692640000006)


D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist

   

6-bromo-3-[4-oxo-4-[4-(2-pyridinyl)-1-piperazinyl]butyl]-2-sulfanylidene-1H-quinazolin-4-one

6-bromo-3-[4-oxo-4-[4-(2-pyridinyl)-1-piperazinyl]butyl]-2-sulfanylidene-1H-quinazolin-4-one

C21H22BrN5O2S (487.06774920000004)


   
   

2-deoxy-N-(naphthalen-1-ylmethyl)guanosine 5-(dihydrogen phosphate)

2-deoxy-N-(naphthalen-1-ylmethyl)guanosine 5-(dihydrogen phosphate)

C21H22N5O7P (487.12567920000004)


   

(6S)-N-[(2S,3R,6R,7R)-3-(Acetyloxymethyl)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]octan-7-yl]-6-[(2-aminoacetyl)amino]-7-hydroxy-7-oxoheptanimidate

(6S)-N-[(2S,3R,6R,7R)-3-(Acetyloxymethyl)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]octan-7-yl]-6-[(2-aminoacetyl)amino]-7-hydroxy-7-oxoheptanimidate

C19H27N4O9S- (487.1498672)


   

5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[4-(methylsulfonyl)phenyl]methoxy]-2-thiophenecarboxamide

5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[4-(methylsulfonyl)phenyl]methoxy]-2-thiophenecarboxamide

C22H21N3O6S2 (487.08717260000003)


   

2,2,2-Trifluoro-N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)-2-propanyl)acetamide

2,2,2-Trifluoro-N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)-2-propanyl)acetamide

C25H21F4N3O3 (487.15189640000006)


   

2-[[5-cyano-7-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidin-4-yl]amino]butanedioic acid

2-[[5-cyano-7-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidin-4-yl]amino]butanedioic acid

C16H18N5O11P (487.0740408)


   
   

Malvidin 3-alpha-L-galactoside

Malvidin 3-alpha-L-galactoside

C25H27O10+ (487.1604142)


   

2-pyridin-4-yl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide

2-pyridin-4-yl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide

C24H17N5O3S2 (487.07727719999997)


   

(E)-3-(4-fluorophenyl)-N-[[4-[(3-methoxypyrazin-2-yl)sulfamoyl]phenyl]carbamothioyl]prop-2-enamide

(E)-3-(4-fluorophenyl)-N-[[4-[(3-methoxypyrazin-2-yl)sulfamoyl]phenyl]carbamothioyl]prop-2-enamide

C21H18FN5O4S2 (487.07842)


   

N-[(1-ethyl-2-oxo-6-benzo[cd]indolyl)sulfonyl]-N-(4-methoxyphenyl)-3-pyridinecarboxamide

N-[(1-ethyl-2-oxo-6-benzo[cd]indolyl)sulfonyl]-N-(4-methoxyphenyl)-3-pyridinecarboxamide

C26H21N3O5S (487.12018560000007)


   

2-[[4-methyl-5-[4-(4-morpholinylsulfonyl)phenyl]-1,2,4-triazol-3-yl]thio]-N-(4-methylphenyl)acetamide

2-[[4-methyl-5-[4-(4-morpholinylsulfonyl)phenyl]-1,2,4-triazol-3-yl]thio]-N-(4-methylphenyl)acetamide

C22H25N5O4S2 (487.134789)


   

N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-{[5-(2-hydroxyphenyl)-4-phenyl-4H-1,2,4-triazol-3-yl]sulfanyl}acetamide

N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-{[5-(2-hydroxyphenyl)-4-phenyl-4H-1,2,4-triazol-3-yl]sulfanyl}acetamide

C25H21N5O2S2 (487.1136606)


   

5-Acetyl-2-[2-(6-fluoro-9H-1,3,4,9-tetraaza-fluoren-2-ylsulfanyl)-acetylamino]-4-methyl-thiophene-3-carboxylic acid ethyl ester

5-Acetyl-2-[2-(6-fluoro-9H-1,3,4,9-tetraaza-fluoren-2-ylsulfanyl)-acetylamino]-4-methyl-thiophene-3-carboxylic acid ethyl ester

C21H18FN5O4S2 (487.07842)


   
   
   

[(1R)-1-ethylsulfonyl-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-(4-fluorophenyl)methanone

[(1R)-1-ethylsulfonyl-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-(4-fluorophenyl)methanone

C24H26FN3O5S (487.1577118000001)


   

[(1S)-1-ethylsulfonyl-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-(4-fluorophenyl)methanone

[(1S)-1-ethylsulfonyl-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-(4-fluorophenyl)methanone

C24H26FN3O5S (487.1577118000001)


   
   

3,5-dideoxy-5-glycolamido-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-D-galacto-hexopyranose

3,5-dideoxy-5-glycolamido-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-D-galacto-hexopyranose

C17H29NO15 (487.1537124)


   

3,5-dideoxy-5-glycolamido-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-alpha-D-galacto-hexopyranose

3,5-dideoxy-5-glycolamido-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-alpha-D-galacto-hexopyranose

C17H29NO15 (487.1537124)


   
   

4,7-DI(Para-ethoxyphenyl)-6-(ortho-chlorophenyl)-1,2,5-thiadiazolo(3,4-C)pyridine

4,7-DI(Para-ethoxyphenyl)-6-(ortho-chlorophenyl)-1,2,5-thiadiazolo(3,4-C)pyridine

C27H22ClN3O2S (487.11211820000005)


   
   

CDP-choline(1-)

CDP-choline(1-)

C14H25N4O11P2 (487.099502)


Conjugate base of CDP-choline(1+) arising from deprotonation of the diphosphate function.

   
   

Fulimetibant

Fulimetibant

C25H21F4N3O3 (487.15189640000006)


Fulimetibant is a bradykinin receptor antagonist[1].